Skip to main content

Fiscal Wizard · Single-issue tearsheet

SMTI / Jun 20, 2026 Run #7212

SMTI

Sanara MedTech Inc.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Composite verdict

F 19.2 / 100
Bearish setup · Trend Following 11 drivers · 6 gates blocking
  • Trendline Break
  • MA Rejection
  • Chaikin Money Flow
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 35th of 57 in Medical Instruments & Supplies

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 13Mean-reversion Neutral 46

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -92%
Asset value $0.65Earnings power value $3.79Price $22.02

Priced above its no-growth earnings power value ($3.79/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

37.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Margin of Safety 0
Asset Turnover 92
EV/FCF 0
Greenblatt ROC 80
EPS Growth (YoY) 0

Technicals Bearish

0.7 / 100

Bearish setup leads (Trendline Break, MA Rejection, Chaikin Money Flow); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Trendline Break 6
MA Rejection 9
Accumulation/Distribution Line 11

Risk Gates

6 blocking 8 caution

6 guards active, 22 signals gated.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SMTI.